| Ex-Date | Purpose |
|---|---|
26-05-2021 | Audited Results |
12-08-2021 | Quarterly Results |
11-11-2021 | Quarterly Results |
09-02-2022 | Quarterly Results |
25-05-2022 | Quarterly Results & Audited Results |
04-08-2022 | Quarterly Results |
14-11-2022 | Quarterly Results |
09-02-2023 | Quarterly Results |
25-05-2023 | Audited Results & Quarterly Results |
09-08-2023 | Quarterly Results & Buy Back of Shares |
08-11-2023 | Quarterly Results |
07-02-2024 | Quarterly Results |
06-11-2024 | Quarterly Results |
06-11-2024 | Interim Dividend |
12-02-2025 | Quarterly Results |
28-05-2025 | Audited Results |
07-08-2025 | Quarterly Results |
05-11-2025 | Quarterly Results |
05-02-2026 | Interim Dividend & Quarterly Results |
27-05-2026 | Audited Results |
05-08-2026 | Quarterly Results |
27-10-2026 | Buy Back of Shares & Quarterly Results |
News
FDC informs about certificate
FDC informs about disclosure on SAST
FDC - Quaterly Results
FDC reports Profit after tax of Rs 1320.20 Mln, in the June 2026 quarter
FDC informs about disclosures
FDC informs about disclosure
FDC - Quaterly Results
FDC reports Profit after tax of Rs 1070.70 Mln, in the March 2026 quarter
FDC informs about board meeting
FDC gets USFDA’s nod for Cefixime for Oral Suspension
The company has received abbreviated new drug application approval from USFDA
FDC informs about ANDA approval
FDC informs about postal ballot
FDC informs about certificate
FDC informs about disclosure
FDC informs about disclosure
FDC - Quaterly Results
FDC reports Profit after tax of Rs 271.87 Mln, in the December 2025 quarter
FDC informs about board meeting
FDC secures USFDA’s nod for Fluconazole Tablets
The company has received abbreviated new drug application approval from USFDA
FDC informs about press release
FDC reports Profit after tax of Rs 294.75 Mln, in the September 2025 quarter
FDC secures ANDA approval from USFDA
The company has secured ANDA approval for Pilocarpine Hydrochloride Ophthalmic Solution USP
FDC - Quaterly Results
FDC - Quaterly Results
FDC reports Profit after tax of Rs 1221.90 Mln, in the June 2025 quarter
FDC - Quaterly Results
FDC informs about board meeting
FDC informs about press release
FDC - Quaterly Results
FDC - Quaterly Results
FDC - Quaterly Results
FDC reports Profit after tax of Rs 482.15 Mln, in the March 2025 quarter
FDC informs about board meeting
FDC recalling 60,428 bottles of Timolol Maleate Ophthalmic Solution in US market
The drugmaker initiated the Class II nationwide (US) recall on April 18, 2025
FDC informs about compliances certificate
FDC reports Profit after tax of Rs 364.48 Mln, in the December 2024 quarter
FDC - Quaterly Results
FDC - Quaterly Results
FDC - Quaterly Results
FDC informs about board meeting
FDC informs about certificate
FDC informs about compliances-certificate
FDC informs about issuance of duplicate share certificates
FDC informs about closure of trading window
FDC inches up on getting final nod for Cefixime 400 mg Tablets
The company has received final approval from U.S. Food and Drug Administration
FDC gets final nod for Cefixime 400 mg Tablets
The company has received final approval from U.S. Food and Drug Administration
FDC informs about disclosure
FDC informs about loss of share certificate
FDC submits intimation of company’s new correspondence address
FDC falls on the bourses
The company is recalling 1,55,232 bottles of Timolol Maleate ophthalmic solution in the US market
FDC recalling 1,55,232 bottles of Timolol Maleate ophthalmic solution in US market
The company initiated the Class II recall on October 29, 2024
FDC - Quaterly Results
FDC reports Profit after tax of Rs 739.73 Mln, in the September 2024 quarter
FDC - Quaterly Results
FDC - Quaterly Results
FDC informs about disclosure
FDC - Quaterly Results
FDC - Quaterly Results
FDC reports Profit after tax of Rs 783.76 Mln, in the December 2023 quarter
FDC - Quaterly Results
FDC informs about certificate
FDC informs about details of loss of certificate
FDC submits investor presentation
FDC reports Profit after tax of Rs 720.41 Mln, in the September 2023 quarter
FDC - Quaterly Results
FDC - Quaterly Results
FDC informs about post offer public announcement
FDC - Quaterly Results
FDC reports Profit after tax of Rs 1085.51 Mln, in the June 2023 quarter
FDC - Quaterly Results
FDC submits board meeting intimation
FDC informs about details of loss of certificate
FDC gets EIR from USFDA for Aurangabad manufacturing facility
USFDA had conducted an inspection at said manufacturing facility from February 6, 2023 to February 12, 2023
FDC gets EIR from USFDA for Roha manufacturing facility
USFDA had conducted an inspection at said manufacturing facility from March 20, 2023 to March 24, 2023
FDC informs about newspaper advertisement
FDC reports Profit after tax of Rs 372.41 Mln, in the March 2023 quarter
FDC - Quaterly Results
FDC - Quaterly Results
FDC informs about non-applicability of large corporate entity
FDC informs about compliance certificate
FDC informs about updates
USFDA conducts inspection of FDC’s manufacturing unit at Roha
The said audit has been successfully completed by the USFDA with ’No observations’
USFDA completes inspection at FDC’s manufacturing plant
The said audit has been successfully completed by the USFDA with No observations
FDC - Quaterly Results
FDC - Quaterly Results
FDC - Quaterly Results
FDC informs about board meeting
FDC informs about trading window closure
FDC informs about loss of share certificate
FDC trades higher on the BSE
FDC’s brand ZIFI has been awarded with Certificate of Excellence at AWACS 2022
FDC’s brand ZIFI awarded with Certificate of Excellence at AWACS 2022
FAVENZA was recognized for New Introduction of the Year in Acute Therapy